Varun Sureja1, Dharmeshkumar Kheni1, Divyanshu Prajapati1, Mayank Rajawat1, Ajit Magar1, Asha Krishnaraj1, Ashish Sirsikar2, A Arun Prasath3, Amit Mishra4, Anil Singh Rajput5, Balasubramanian Vijayakrishnan6, Chetan Puram7, D Manoj Kumar8, Diwakar Agarwal9, Girish Shiragambhi10, Jitendra Patil11, K Ravichandran12, Kailash Nath Jain13, M Thayaga Raju14, Rajesh Arora15, S Nawazish16, Sachin Chhabra17, Lakshminarayan Shyam18, Sudarshan Is19, Vinay Aggarwal20. 1. Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India. 2. Department of Orthopedics, N.S.C.B Medical College, Jabalpur, India. 3. Department of Orthopedics, APJ Multi-Speciality Hospital, Walajabad, India. 4. Department of Orthopedics, Suchak Hospital, Mumbai, India. 5. Department of Orthopedics, Rajput Fracture, Joint & Trauma Clinic, Gwalior, India. 6. Department of Orthopedics, Lifespan Bone & Joint Clinic, Chennai, India. 7. Department of Orthopedics, Sancheti Institiute for Orthopaedic & Rehabilitation, Pune, India. 8. Department of Orthopedics, Shri Kanaka Mahalaxmi Nursing Home, Vizag, India. 9. Department of Orthopedics, Diwakar Ortho & General Hospital, Jaipur, India. 10. Department of Orthopedics, Primus Hospital, Bengaluru, India. 11. Department of Orthopedics, Adarsh Nursing Home, Mumbai, India. 12. Deparment of Orthopedics, Jayam Hospital, Madurai, India. 13. Department of Orthopedics, Dr. Jain's Clinic, Delhi, India. 14. Department of Orthopedics, Radhika Clinic, Bengaluru, India. 15. Department of Orthopedics, Newlife Clinic, Delhi, India. 16. Department of Orthopedics, Nuha Hospital, Guntur, India. 17. Department of Orthopedics, Pusp Clinic, Indore, India. 18. Department of Orthopedics, Raksha Hospital, Madurai, India. 19. Department of Orthopedics, Bhargav Orthopedic Center & Banashankari Orthopedic Speciality Service, Bengaluru, India. 20. Department of Orthopedics, Sanjeevani Hospital, Delhi, India.
Abstract
Background: Chronic low back pain (LBP) is the most common musculoskeletal condition affecting a person's quality of life. Over the past decades, a lot of work was done in an attempt to reduce the negative impact of LBP, and help patients recover and maintain a better quality of life. Nevertheless, there is still a lot to be done to fully understand the problem of underlying chronic LBP and a wide gap that exist between basic science and applied rehabilitation research on LBP. Objectives: This was an open label, multicentric, observational, post-marketing surveillance study in a real-world setup designed to evaluate the efficacy and safety of MyrliMax® capsules containing standardised Commiphora myrrha gum resin extract in Indian subjects with chronic LBP varying in intensity. Materials and methods:This study included 204 subjects diagnosed with chronic LBP at the outpatient department of 20 centres under the supervision of a medical doctor. All subjects took MyrliMax® capsules twice daily for 20 days. Visual Analogue Scale (VAS) pain score, rescue medicine requirement, therapy satisfaction scores and safety parameters were assessed as per the schedule. Outcomes:Treatment with MyrliMax® capsules significantly (p<0.01) and progressively reduced the VAS score throughout treatment. A significant pain reduction was observed from the second visit. The mean VAS score was 6.58, 4.66, 2.99 and 1.88 on Day 0, Day 7, Day 14 and Day 20, respectively. A similar trend was also observed in subgroups based on gender and severity score. The need of rescue analgesics/NSAIDs was significantly reduced from the second week, indicating a potential of MyrliMax® capsules to increase the pain threshold. All physicians and patients were satisfied with the efficacy of MyrliMax® capsules assessed by physician's satisfaction score and patient's satisfaction score. There were no significant serious adverse events due to treatment during the study, which indicated that the treatment with MyrliMax® was well tolerated by subjects. Conclusion: MyrliMax® capsule is a potentially effective and safe therapy for pain reduction in patients suffering from chronic LBP. MyrliMax® capsules can be used to reduce pain in NSAIDs intolerant subjects suffering from chronic LBP.
Background: Chronic low back pain (LBP) is the most common musculoskeletal condition affecting a person's quality of life. Over the past decades, a lot of work was done in an attempt to reduce the negative impact of LBP, and help patients recover and maintain a better quality of life. Nevertheless, there is still a lot to be done to fully understand the problem of underlying chronic LBP and a wide gap that exist between basic science and applied rehabilitation research on LBP. Objectives: This was an open label, multicentric, observational, post-marketing surveillance study in a real-world setup designed to evaluate the efficacy and safety of MyrliMax® capsules containing standardised Commiphora myrrhagum resin extract in Indian subjects with chronic LBP varying in intensity. Materials and methods:This study included 204 subjects diagnosed with chronic LBP at the outpatient department of 20 centres under the supervision of a medical doctor. All subjects took MyrliMax® capsules twice daily for 20 days. Visual Analogue Scale (VAS) pain score, rescue medicine requirement, therapy satisfaction scores and safety parameters were assessed as per the schedule. Outcomes:Treatment with MyrliMax® capsules significantly (p<0.01) and progressively reduced the VAS score throughout treatment. A significant pain reduction was observed from the second visit. The mean VAS score was 6.58, 4.66, 2.99 and 1.88 on Day 0, Day 7, Day 14 and Day 20, respectively. A similar trend was also observed in subgroups based on gender and severity score. The need of rescue analgesics/NSAIDs was significantly reduced from the second week, indicating a potential of MyrliMax® capsules to increase the pain threshold. All physicians and patients were satisfied with the efficacy of MyrliMax® capsules assessed by physician's satisfaction score and patient's satisfaction score. There were no significant serious adverse events due to treatment during the study, which indicated that the treatment with MyrliMax® was well tolerated by subjects. Conclusion:MyrliMax® capsule is a potentially effective and safe therapy for pain reduction in patients suffering from chronic LBP. MyrliMax® capsules can be used to reduce pain in NSAIDs intolerant subjects suffering from chronic LBP.
Authors: Stephanie Mathieson; Richard Kasch; Christopher G Maher; Rafael Zambelli Pinto; Andrew J McLachlan; Bart W Koes; Chung-Wei Christine Lin Journal: J Pain Date: 2018-07-03 Impact factor: 5.820
Authors: Jan Hartvigsen; Mark J Hancock; Alice Kongsted; Quinette Louw; Manuela L Ferreira; Stéphane Genevay; Damian Hoy; Jaro Karppinen; Glenn Pransky; Joachim Sieper; Rob J Smeets; Martin Underwood Journal: Lancet Date: 2018-03-21 Impact factor: 79.321
Authors: Martina Rekatsina; Antonella Paladini; Alba Piroli; Panagiotis Zis; Joseph V Pergolizzi; Giustino Varrassi Journal: Pain Ther Date: 2020-01-04